Product Description: TPN171 is a potent, selective and oral bioavailable inhibitor of phosphodiesterase type 5 (PDE5) with an IC50 of 0.62 nM, being developed for the treatment of pulmonary arterial hypertension (PAH)[1].
Applications: Neuroscience-Neuromodulation
Formula: C24H35N5O3
References: [1]Wang Z, et al. Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension. J Med Chem. 2019 May 23;62(10):4979-4990.
CAS Number: 1229018-87-4
Molecular Weight: 441.57
Compound Purity: 99.41
Research Area: Cardiovascular Disease
Solubility: DMSO : 25 mg/mL (ultrasonic;warming;heat to 60°C)
Target: Phosphodiesterase (PDE)